AIM ImmunoTech (FRA:HXB2) Cash Flow from Discontinued Operations : €0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is AIM ImmunoTech Cash Flow from Discontinued Operations?

Cash flow from discontinued operations is the cash received by a company that comes from the sale of part of business.

AIM ImmunoTech's cash flow from discontinued operations for the three months ended in Dec. 2023 was €0.00 Mil. It means AIM ImmunoTech received €0.00 Mil from the sale of part of business quarterly. AIM ImmunoTech's cash flow from discontinued operations for the trailing twelve months (TTM) ended in Dec. 2023 was €0.00 Mil.

AIM ImmunoTech Cash Flow from Discontinued Operations Historical Data

The historical data trend for AIM ImmunoTech's Cash Flow from Discontinued Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AIM ImmunoTech Cash Flow from Discontinued Operations Chart

AIM ImmunoTech Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash Flow from Discontinued Operations

Get a 7-Day Free Trial

AIM ImmunoTech Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash Flow from Discontinued Operations	Get a 7-Day Free Trial															-	-	-	-	-

AIM ImmunoTech Cash Flow from Discontinued Operations Calculation

Cash received by a company that comes from the sale of part of business.

Cash Flow from Discontinued Operations for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

AIM ImmunoTech Cash Flow from Discontinued Operations Related Terms

Thank you for viewing the detailed overview of AIM ImmunoTech's Cash Flow from Discontinued Operations provided by GuruFocus.com. Please click on the following links to see related term pages.

AIM ImmunoTech (FRA:HXB2) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AIM ImmunoTech Inc (FRA:HXB2) » Definitions » Cash Flow from Discontinued Operations

Comparable Companies

Traded in Other Exchanges

AIM:USA

Address

2117 SW Highway 484, Ocala, FL, USA, 34473

Website

https://www.aimimmuno.com

AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders, viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases and drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer and triple negative metastatic breast cancer. The company is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.

AIM ImmunoTech (FRA:HXB2) Headlines

No Headlines